Scarica l'app Stockscreener
2.39
0.84%
0.02
Allogene Therapeutics Inc Borsa (ALLO) Ultime notizie
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Allogene raises $200.4 million in stock offering By Investing.com - Investing.com India
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock - Sahm
Latham & Watkins Advises on Allogene Therapeutics’ US$200.4 Million Public Offering of Common Stock - Latham & Watkins LLP
ALLO Upgraded by JP Morgan -- Rating Changed to Neutral - GuruFocus
Allogene Therapeutics advances allogeneic CAR T interim results in early LBCL consolidation - Traders Union
ALLO Stock Rockets As ALPHA3 CAR‑T Data Reset Expectations - timothysykes.com
Allogene Therapeutics announces closing of $200.4 million public offering of common stock - marketscreener.com
Allogene raises $200.4 million in stock offering - Investing.com
Allogene sold 100.2M shares at $2, bringing in $200.4M - Stock Titan
ALLO Stock Spikes As ALPHA3 CAR‑T Data Resets Expectations - timothysykes.com
ALLO Stock Soars As ALPHA3 CAR‑T Data Electrify Traders - StocksToTrade
ALLO Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
ALLO Stock Soars As ALPHA3 CAR‑T Data Reprices The Story - StocksToTrade
ALLO Stock Soars As ALPHA3 Trial Data Reset Expectations - timothysykes.com
ALLO Stock Rockets As ALPHA3 CAR-T Data Reset Expectations - StocksToTrade
Allogene Therapeutics (NASDAQ:ALLO) Trading Up 13.1% Following Analyst Upgrade - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright cuts Allogene stock price target to $11 from $12 - Investing.com UK
H.C. Wainwright cuts Allogene stock price target to $11 from $12 By Investing.com - Investing.com South Africa
Allogene Therapeutics (NASDAQ:ALLO) Upgraded to "Neutral" at JPMorgan Chase & Co. - MarketBeat
Dell To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
JPMorgan upgrades Allogene stock rating to neutral after pullback By Investing.com - Investing.com South Africa
JPMorgan Upgrades Allogene Therapeutics to Neutral From Underweight - marketscreener.com
HC Wainwright Issues Optimistic Outlook for ALLO Earnings - MarketBeat
JPMorgan upgrades Allogene stock rating to neutral after pullback - Investing.com
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases - Sahm
ALLO Maintained by Jefferies -- Price Target Raised to $10.00 - GuruFocus
$Allogene Therapeutics (ALLO.US)$ - Moomoo
Allogene Therapeutics Prices Large Common Stock Offering - TipRanks
Allogene Therapeutics (ALLO) Is Down 13.0% After $175M Equity Raise On ALPHA3 MRD Data Release – Has The Bull Case Changed? - Yahoo Finance
ALLO Stock Slumps As $175M Secondary Offering Hits Tape - timothysykes.com
ALLO Stock Slides As $175M Equity Offering Hits Tape - StocksToTrade
Allogene prices $175M public offering of common stock at $2.00 per share - TradingView — Track All Markets
[8-K] Allogene Therapeutics, Inc. Reports Material Event - Stock Titan
Allogene Therapeutics (NASDAQ: ALLO) to Sell 87.5M Shares at $2.00 - Stock Titan
Allogene Therapeutics (NASDAQ:ALLO) Shares Gap DownTime to Sell? - MarketBeat
ALLO Stock Drops As $175M Equity Raise Hits Tape - StocksToTrade
Nasdaq Surges 200 Points; Morgan Stanley Posts Upbeat Earnings - Benzinga
Jefferies raises Allogene stock price target to $10 on trial data By Investing.com - Investing.com South Africa
Traders Buy Large Volume of Put Options on Allogene Therapeutics (NASDAQ:ALLO) - MarketBeat
Jefferies raises Allogene stock price target to $10 on trial data - Investing.com
ALLO Stock Slides As $175M Equity Raise Hits Tape - StocksToTrade
Allogene publishes preclinical data for autoimmune CAR T therapy By Investing.com - Investing.com Australia
ALLO stock hits 2-year highs – analyst calls Allogene’s phase 2 trial data to treat lymphoma a ‘home run’ - MSN
Allogene publishes preclinical data for autoimmune CAR T therapy - Investing.com
Autoimmune drug candidate cleared B and T cells in lupus models - Stock Titan
Allogene Therapeutics (NASDAQ:ALLO) Upgraded to Strong-Buy at Jefferies Financial Group - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Sees Significant Growth in Short Interest - MarketBeat
ALLO Seeks Capital with a New Offering Below Previous Close - GuruFocus
Allogene Therapeutics Prices $175 Million Public Offering - marketscreener.com
Allogene Therapeutics Shares Slide on Up to $201.3M Public Offering - Moomoo
Allogene Therapeutics prices $175M stock offering at $2 per share - MSN
Biotech Allogene sells 87.5M shares at $2 to raise $175M - Stock Titan
Allogene prices $175 million stock offering at $2 per share By Investing.com - Investing.com South Africa
ALLO Maintained by Argus Research -- Price Target Raised to $3.8 - GuruFocus
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock - Bitget
Allogene Therapeutics, Inc. Prices Public Offering of 87.5 Million Shares at $2.00 per Share - Quiver Quantitative
Allogene prices $175 million stock offering at $2 per share - Investing.com
Allogene Therapeutics announces pricing of public offering of common stock - marketscreener.com
Allogene Therapeutics Announces Pricing Of Public Offering Of Common Stock - TradingView — Track All Markets
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewswire Inc.
Pfizer in deal with Allogene to develop cancer cell therapies - AOL.com
ALLO Maintained by Citizens -- Price Target Raised to $8.00 - GuruFocus
2.19%
0.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):